잠시만 기다려 주세요. 로딩중입니다.

Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas

대한혈액학회지 2016년 51권 3호 p.187 ~ 192
이지영 ( Lee Ji-Young ) - Inje University Busan Paik Hospital Department of Internal Medicine

이상민 ( Lee Sang-Min ) - Inje University Busan Paik Hospital Department of Internal Medicine
최문영 ( Choi Moon-Young ) - Inje University Busan Paik Hospital Department of Internal Medicine
김기향 ( Kim Ki-Hyang ) - Inje University Busan Paik Hospital Department of Internal Medicine
주영돈 ( Joo Young-Don ) - Inje University Haeundae Paik Hospital Department of Hematology-Oncology
 ( Im Sung-Nam ) - Inje University Haeundae Paik Hospital Department of Hematology-Oncology
이원식 ( Lee Won-Sik ) - Inje University Busan Paik Hospital Department of Internal Medicine

Abstract


Background: This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs).

Methods: Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed.

Results: The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality.

Conclusion: IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.

키워드

Peripheral T-cell lymphomas; IMEP; Ifosphamide; Etoposide; Prednisolone
원문 및 링크아웃 정보
  
등재저널 정보